Three small-cap stocks that can make a giant leap in 2021

Be the First to Comment Read

Three small-cap stocks that can make a giant leap in 2021

 Three small-cap stocks that can make a giant leap in 2021

Source:TypoArt BS ,Shutterstock

Summary

  • With 2021 expected to be less volatile than the previous year post vaccine roll-out, small-cap stocks could come under the spotlight.
  • Luminar Technologies shares have grown nearly 258% in the last year. The Company recently collaborated with Volvo cars to release ‘Cirrus’.
  • 111, Inc. ADS grew massively last year. Lately, it entered into a strategic partnership with Jilin Baiyi Doctor Group to offer SMART-enabled healthcare services and doctor-patient management in Northeast China.
  • Simulations Plus recently released GastroPlus® and also signed a supply agreement to distribute MonolixSuite™ in China.

Despite being highly volatile and risky, small-cap stocks offer investors a chance to outrun institutional investors via considerable growth opportunities. Historically, these stocks have done better than the large-cap and mid-cap players.

In this article, we have cherry-picked three US small-cap stocks with significant progress in the past seem well placed for the upcoming period.

Luminar Technologies, Inc.

A global frontrunner in automotive lidar hardware & software technology, Luminar Technologies (NASDAQ:LAZR) has seen its stock rise significantly in the last 12 months. LAZR shares jumped from US$10.55 on 18 February 2020 to US$37.73 on 12 February 2021, up 257.63%.

On a YTD basis, the stock has generated an impressive 20.39% growth aided by some important announcements.

LAZR’s Recent Developments

Appointment to the Board

On 12 February 2021, Luminar added two leaders to its Board, Katharine “Katie” A. Martin and Dr. Mary Lou Jepsen, to drive the Company towards its vision.

Katharine “Katie” A. Martin is the chairperson of the Board of Wilson Sonsini Goodrich & Rosati. On the other hand, Dr. Mary Lou Jepsen is the CEO, Founder and Chairperson of the Board of medical laser imaging device company, Openwater. She is also the Director at Lear Corporation.

Collaboration with Volvo Cars

In January, Luminar Technologies and Volvo Cars published a curated dataset (Cirrus) comprising exclusive lidar data from data collection fleet of Volvo Cars. This dataset is accessible to industry developers as well as researchers to support and additional advancement for secure self-driving.

Cirrus contains unprocessed data from Luminar’s high-performance lidar sensors. It can accurately identify objects before the car that is 250 meters away. The dataset is anticipated to assist advance research & improvement of self-driving software algorithm, to achieve enhanced vehicle security at highway speeds and complicated atmospheres.

Source: © Ronstik | Megapixl.com

111, Inc.

Leading tech-enabled healthcare platform company, 111, Inc (NASDAQ:YI) noted a massive growth in its ADS price in the last one year, especially after 15 January 2021. The shares which traded at US$7.2 on 18 February 2020 reached US$27.33 on 16 February, representing a growth of around 279.48%. The price has seen a massive surge in the last month driven by significant announcements.

Strategic Partnership with Jilin Baiyi Doctor Group

On 05 February 2021, 111, Inc. entered a strategic partnership with Jilin Baiyi Doctor Group Management Co., Ltd to offer SMART-enabled healthcare services along with the management of doctor-patient in Northeast China.

The deal between the two parties would let patients easily access a comprehensive suite of healthcare services, ranging from online medical consultations to diagnosis, treatment, and follow-up treatment, via the same platform.

Further, in maintaining the companies’ strong commitment to increasing the availability of quality healthcare services for patients nationwide, 111, Inc., and Jilin Baiyi Doctor Group Management Co, would together look for added internet-based innovative models intended to attain that mutual goal.

Simulations Plus Inc

Simulations Plus, Inc. (Nasdaq:SLP), a leading modeling & simulation software and consulting services provider, witnessed its stock surge 124.10% in the last 12 months from US$37.63 on 18 February 2020 to US$84.33 on 16 February 2021. Let’s have a look at the Company’s latest developments.

SLP releases latest version of GastroPlus®

On 09 February 2021, Simulations Plus, Inc., declared the release of GastroPlus® version 9.8.1 as part of its physiologically based biopharmaceutics/pharmacokinetics modeling program.

In this version, the key improvement involves:

  • Methods, verification, and guidance for its proven drug-drug interaction (DDI) models.
  • A new choice to involve inconsistency in lung deposition in the Population Simulator.
  • New improvements when introducing chemical structures.
  • Revised possibility contour results for the Population Simulator.
  • Added units for Cmax, AUC0-inf along with AUC0-t in .beq files for personal crossover tests & virtual bioequivalence summaries.
  • Added metabolite Cmax, AUC0-inf & AUC0-t in .beq files for personal crossover tests & VBE summaries.
  • Fixed bugs detected by the users and scientists.

Agreement with Mosim

On 02 February 2021, the Company signed a distribution agreement with Mosim to distribute MonolixSuite™ in China.

Source: Copyright © 2021 Kalkine Media Pty Ltd.

MonolixSuite™ is the pharmacokinetic/pharmacodynamic (PK/PD) modeling platform of the Lixoft division. It is a unique solution for non-compartmental analysis, PK/PD along with population modeling for Clinical Pharmacology & Pharmacometrics that encourages the pharmacometricians’ efforts to control their ventures from the earliest data exploration till clinical trial simulations.

This distribution arrangement with Mosim for MonolixSuite will add to the current deal between Simulations Plus & PharmoGo Co., Limited. For information, PharmoGo Co is a China-based distributor for the SLP’s software products, involving GastroPlus® along with ADMET Predictor®. It is supporting the Company in improving its reach discovery, pre-clinical and clinical research along with the development within the pharma industry in China.

Disclaimer

Speak your Mind

Featured Articles